IXICO plc (IXI) AI Stock Analysis

• Market Cap: £10.43M
• Dividend Yield: N/A
• Average Volume (3M): 123.87K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.95
• Revenue Growth: 7.27%
• EPS Growth: 39.64%
• Country: UK
• Employees: 81
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.01
• Shares Outstanding: 92,668,594
• 10 Day Avg. Volume: 82,815
• 30 Day Avg. Volume: 123,868
• PEG Ratio: -0.03
• Price to Book (P/B): 0.47
• Price to Sales (P/S): 0.78
• P/FCF Ratio: -2.03
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 48 Neutral
• Price Target: 12.00p ▲(6.67% Upside)

IXICO plc's overall stock score reflects significant financial challenges, particularly in revenue generation and profitability, which are the most impactful factors. Technical indicators suggest a lack of strong momentum, and valuation metrics highlight profitability issues. The absence of earnings call data and corporate events limits additional insights.

IXICO plc Business Overview & Revenue Model

Company Description

IXICO plc provides data analytics services to the biopharmaceutical industry in the United Kingdom, Switzerland, Netherlands, Ireland, rest of Europe, the United States, and internationally. Its services include collection, analysis, management, and reporting on data generated in the course of a clinical study. The company's technologies comprise Assessa, a secure online digital platform that provides clinical decision support for patient selection and post-marketing surveillance; and TrialTracker, a platform that delivers imaging services designed to manage the complex imaging workflow from image upload, quality control, and reading/analysis to reporting and data transfer. Its focused therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis and other demyelinating diseases, Progressive Supranuclear Palsy, and other rare neurological diseases. The company also engages in the data collection, optimization, and analytics of rare neurological disorders; offers drug development analytics, imaging operation services, and post marketing surveillance services, as well as consultancy services; and provides end-to-end services, such as trail design and consultation, project management, imaging site set-up and management, data management, reading and analysis, and regulatory pathway. IXICO plc was incorporated in 1995 and is based in London, the United Kingdom.

How the Company Makes Money

IXICO generates revenue primarily through contracts with pharmaceutical and biotechnology companies for its imaging and data analytics services. The company's revenue model is based on a combination of fee-for-service agreements, project-based contracts, and long-term partnerships with clients involved in clinical trials. Key revenue streams include payments for image acquisition and analysis, data management services, and consulting for trial design and implementation. Additionally, IXICO may benefit from collaborations and partnerships with research institutions and other healthcare organizations, which can lead to increased project opportunities and shared resources, further enhancing its earnings potential.

IXICO plc Financial Statement Overview

Summary

IXICO plc is facing financial challenges with a significant decline in revenue and negative profit margins, indicating operational inefficiencies. Despite a strong equity position, the negative cash flow and profitability issues highlight the need for strategic improvements.

Income Statement

The company has experienced a significant decline in revenue over the past year, with a negative revenue growth rate of 13.48% from 2023 to 2024. Both EBIT and EBITDA margins are negative, indicating operational challenges and inefficiencies. The net profit margin is also negative, reflecting ongoing struggles to achieve profitability.

Balance Sheet

The company maintains a strong equity position with an equity ratio of 84.57%, indicating financial stability. However, the debt-to-equity ratio is low at 0.03, suggesting limited leverage which could restrict growth opportunities. Return on Equity is negative, further highlighting profitability issues.

Cash Flow

The company has faced a substantial decline in free cash flow, dropping from -1.66 million in 2023 to -2.20 million in 2024. The operating cash flow to net income ratio is negative, indicating cash flow difficulties. Additionally, the free cash flow to net income ratio suggests challenges in converting earnings to cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.44M	5.77M	6.67M	8.64M	9.19M	9.53M
Gross Profit	3.15M	2.71M	3.27M	4.77M	5.53M	5.91M
EBITDA	-1.02M	-1.95M	-707.00K	1.24M	1.73M	674.00K
Net Income	-1.55M	-2.00M	-1.18M	1.03M	1.51M	952.00K
Balance Sheet
Total Assets	14.08M	11.19M	12.99M	14.65M	14.26M	12.10M
Cash, Cash Equivalents and Short-Term Investments	5.01M	1.79M	4.03M	5.77M	6.68M	7.95M
Total Debt	275.00K	314.00K	387.00K	516.00K	597.00K	213.00K
Total Liabilities	1.79M	1.72M	1.56M	2.16M	2.78M	2.98M
Stockholders Equity	12.29M	9.46M	11.43M	12.49M	11.48M	9.12M
Cash Flow
Free Cash Flow	-733.00K	-2.20M	-1.66M	-815.00K	-1.54M	795.00K
Operating Cash Flow	-701.00K	-1.73M	302.00K	1.43M	614.00K	1.94M
Investing Cash Flow	-414.00K	-377.00K	-1.86M	-2.25M	-2.15M	-1.14M
Financing Cash Flow	3.55M	-134.00K	-156.00K	-114.00K	270.00K	-112.00K

IXICO plc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 11.25
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:IXI, the sentiment is Negative. The current price of 11.25 is below the 20-day moving average (MA) of 11.86, below the 50-day MA of 12.08, and above the 200-day MA of 10.92, indicating a neutral trend. The MACD of -0.24 indicates Positive momentum. The RSI at 34.47 is Neutral, neither overbought nor oversold. The STOCH value of 13.89 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:IXI.

IXICO plc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IXI	―	£10.43M	-4.83	-13.85%	―	7.27%	39.64%
APTA	―	£24.27M	―	-213.66%	―	39.88%	81.33%
FAB	―	£14.49M	―	-139.16%	―	72.98%	55.36%
OBD	―	£6.36M	-0.11	-333.59%	―	45.22%	55.71%

IXICO plc Corporate Events

IXICO Reports Strong Revenue Growth and Strategic Investments in FY25

IXICO plc announced a trading update for the financial year ended September 30, 2025, reporting a 13% increase in revenues to £6.5 million, exceeding market expectations. The company secured new contracts and extended existing ones, contributing to a year-end order book of £13.8 million. With a year-end cash position of £3.5 million, IXICO also completed a capital raise, enabling investments in growth areas. The company anticipates a slightly improved EBITDA loss of no more than £1.6 million, reflecting strategic investments aimed at sustaining growth. CEO Bram Goorden expressed optimism about continued growth and value creation in the neurodegenerative disease biopharma R&D market.

The most recent analyst rating on (GB:IXI) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on IXICO plc stock, see the GB:IXI Stock Forecast page.

IXICO Secures £1.2 Million in New Contracts and Extensions

IXICO plc announced a new commercial contract and a contract extension worth a combined £1.2 million, strengthening its position in the blood-based biomarker field and Alzheimer’s Disease clinical trials. This development is part of IXICO’s ‘Innovate, Lead, Scale’ strategy, reflecting the company’s growing demand and expertise in the field, and enhancing its long-term order book with major biopharma clients.

The most recent analyst rating on (GB:IXI) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on IXICO plc stock, see the GB:IXI Stock Forecast page.

IXICO plc to Host Capital Markets Day Highlighting Growth Strategy and Technological Advancements

IXICO plc announced it will host a Capital Markets Day on 30 October 2025, offering insights into its growth strategy, technology roadmap, and future direction in the neuroscience field. The event will feature presentations from IXICO’s senior management, key customers, and industry leaders, highlighting the company’s AI-driven precision medicine technology platform and expansion opportunities. Existing and prospective investors can join via a live webcast, with the opportunity to engage with the company through a Q&A session.

The most recent analyst rating on (GB:IXI) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on IXICO plc stock, see the GB:IXI Stock Forecast page.

IXICO plc Secures Major Contracts in Alzheimer’s and Friedreich’s Ataxia Trials

IXICO plc has secured two significant contracts valued at approximately £1.3 million to provide neuroimaging services for clinical trials in Alzheimer’s Disease and Friedreich’s Ataxia. These contracts reflect the company’s strategic focus on expanding its global presence and reinforcing its leadership in the neurodegenerative disease space. The first contract involves managing and analyzing imaging for a Phase 1 Alzheimer’s trial over three and a half years, while the second contract supports a Phase 1b trial for Friedreich’s Ataxia over six years. These developments highlight IXICO’s innovative platform and its role as a thought leader in the field.